Tan K A L, Turner K J, Saunders P T K, Verhoeven G, De Gendt K, Atanassova N, Sharpe R M
MRC Human Reproductive Sciences Unit, Centre for Reproductive Biology, University of Edinburgh, Edinburgh EH16 4SB, Scotland, United Kingdom.
Biol Reprod. 2005 May;72(5):1151-60. doi: 10.1095/biolreprod.104.037689. Epub 2005 Jan 19.
Regulation of spermatogenesis involves stage-dependent androgen action on Sertoli cells, but the pathways involved are unclear. We assessed if cyclin D2 could play a role. In rats, Sertoli cell nuclear, stage-dependent immunoexpression of cyclin D2 switched on after Day 10 and persisted through Day 35, but disappeared by adulthood. However, ethane dimethane sulfonate (EDS)-induced testosterone withdrawal in adult rats for 6 days induced stage-dependent cyclin D2 immunoexpression in Sertoli cells, with highest expression at stages IX-XII and nondetectable at stages VI-VIII (opposite that for androgen receptor [AR] immunoexpression). In EDS-treated rats, a single injection of testosterone but not of estrogen reversed this change in 4 h, and testosterone administration from the time of EDS treatment prevented expression of cyclin D2 in Sertoli cells. The EDS-induced changes in cyclin D2 immunoexpression were matched by changes in expression of Ccnd2 (cyclin D2) mRNA in isolated stage-dissected tubules. Treatment of adult rats with flutamide induced stage-dependent cyclin D2 immunoexpression in Sertoli cells within 18 h, and confocal microscopy revealed that immunoexpression of AR and cyclin D2 were mutually exclusive within individual seminiferous tubules in these animals. Sertoli cell-selective ablation of the AR in mice using Cre/loxP technology also resulted in stage-dependent Sertoli cell cyclin D2 immunoexpression. Downstream from cyclin D2 action is retinoblastoma 1 (RB1), a tumor suppressor protein, immunoexpression of which paralleled stage-dependent AR expression in Sertoli cells; RB1 stage specificity disappeared after EDS treatment. These results point to a non-cell cycle role for cyclin D2 and RB1 in mature Sertoli cells in the stage-dependent mechanisms regulated by AR expression and androgen action.
精子发生的调控涉及雄激素对支持细胞的阶段性作用,但其相关途径尚不清楚。我们评估了细胞周期蛋白D2是否能发挥作用。在大鼠中,支持细胞核内细胞周期蛋白D2的阶段性免疫表达在第10天后开启,并持续至第35天,但在成年后消失。然而,成年大鼠经乙烷二甲磺酸盐(EDS)诱导睾酮缺乏6天,可诱导支持细胞中细胞周期蛋白D2的阶段性免疫表达,在第IX - XII阶段表达最高,在第VI - VIII阶段未检测到(与雄激素受体[AR]免疫表达相反)。在经EDS处理的大鼠中,单次注射睾酮而非雌激素可在4小时内逆转这种变化,并且从EDS处理时开始给予睾酮可阻止支持细胞中细胞周期蛋白D2的表达。EDS诱导的细胞周期蛋白D2免疫表达变化与分离的分段生精小管中Ccnd2(细胞周期蛋白D2)mRNA表达的变化相匹配。用氟他胺处理成年大鼠可在18小时内诱导支持细胞中细胞周期蛋白D2的阶段性免疫表达,共聚焦显微镜显示,在这些动物的单个生精小管内,AR和细胞周期蛋白D2的免疫表达相互排斥。使用Cre/loxP技术在小鼠中对支持细胞进行AR选择性消融也导致了支持细胞中细胞周期蛋白D2的阶段性免疫表达。细胞周期蛋白D2作用的下游是视网膜母细胞瘤1(RB1),一种肿瘤抑制蛋白,其免疫表达与支持细胞中AR的阶段性表达平行;EDS处理后RB1的阶段特异性消失。这些结果表明,在由AR表达和雄激素作用调控的阶段性机制中,细胞周期蛋白D2和RB1在成熟支持细胞中具有非细胞周期作用。